MedTrace Logo

Feasibility of Early Gabapentin as an Intervention for Neurorecovery

NCT05302999 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2025-12-02

No results posted yet for this study

Summary

The objective of the proposed study is to conduct the first ever prospective, dose-exploration trial to test the feasibility of early administration of gabapentin as an intervention for neurorecovery. This research project falls under the Intervention Development stage of research as the primary goal is to assess the feasibility of conducting a well-designed intervention efficacy study in the future.

Conditions

  • Spinal Cord Injuries

Interventions

DRUG

Gabapentin

Generic gabapentin

DRUG

Placebo

Inert cellulose

Sponsors & Collaborators

  • National Institute on Disability, Independent Living, and Rehabilitation Research

    collaborator FED

  • MetroHealth Medical Center

    lead OTHER

Principal Investigators

  • Dr. Kimberly Anderson, PhD · Metrohealth Medical Center-Case Western Reserve University School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-14
Primary Completion
2026-08-31
Completion
2026-08-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05302999 on ClinicalTrials.gov